佰金生命科学公布中期业绩 拥有人应占溢利217.3万港元 同比扭亏为盈

Group 1 - The core viewpoint of the article is that Baijin Life Sciences (01466) reported a decrease in revenue but achieved profitability in the latest interim results [1] Group 2 - The company reported revenue of HKD 55.145 million for the six months ending September 30, 2025, representing a year-on-year decrease of 22.22% [1] - The profit attributable to the owners of the company was HKD 2.173 million, marking a turnaround from a loss to profit compared to the previous period [1] - Earnings per share were reported at HKD 0.028 [1] - The turnaround to profitability was primarily due to the fair value changes of convertible bonds, which offset the decline in gross profit [1]